Published in Prostaglandins Leukot Essent Fatty Acids on October 22, 2009
Resolvins and protectins in inflammation resolution. Chem Rev (2011) 3.09
Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol (2011) 1.52
Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol (2012) 0.92
Proresolving nanomedicines activate bone regeneration in periodontitis. J Dent Res (2014) 0.87
Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent. Am J Physiol Lung Cell Mol Physiol (2015) 0.86
Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease. Cell Metab (2015) 0.84
Bioactive Compounds Isolated from Microalgae in Chronic Inflammation and Cancer. Mar Drugs (2015) 0.82
Protective effects of n-6 fatty acids-enriched diet on intestinal ischaemia/reperfusion injury involve lipoxin A4 and its receptor. Br J Pharmacol (2014) 0.79
Effects of n-3 PUFAs on Intestinal Mucosa Innate Immunity and Intestinal Microbiota in Mice after Hemorrhagic Shock Resuscitation. Nutrients (2016) 0.77
Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol Aspects Med (2017) 0.76
Lipoxin A4 Preconditioning Attenuates Intestinal Ischemia Reperfusion Injury through Keap1/Nrf2 Pathway in a Lipoxin A4 Receptor Independent Manner. Oxid Med Cell Longev (2016) 0.76
Inflammatory bowel disease. N Engl J Med (2002) 21.17
Seven-transmembrane receptors. Nat Rev Mol Cell Biol (2002) 11.50
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol (2008) 11.02
Points of control in inflammation. Nature (2002) 10.61
Resolution of inflammation: the beginning programs the end. Nat Immunol (2005) 9.81
Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature (2007) 6.53
Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol (2007) 5.83
Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov (2004) 5.08
New drugs for rheumatoid arthritis. N Engl J Med (2004) 4.38
Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol (2005) 4.30
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A (2010) 3.60
Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol (2000) 3.07
Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med (2002) 2.94
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol (2004) 2.86
The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev (2006) 2.80
Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry (1995) 2.75
Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci U S A (1999) 2.21
Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol (2009) 2.21
Concern A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A (2004) 2.13
The pathophysiology of aortic cross-clamping and unclamping. Anesthesiology (1995) 1.93
Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J Exp Med (1996) 1.92
Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J Biol Chem (1997) 1.66
Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest (1999) 1.64
Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med (1999) 1.55
Resolvin E1 metabolome in local inactivation during inflammation-resolution. J Immunol (2008) 1.52
Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation. J Biol Chem (2000) 1.35
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology (2002) 1.33
Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol (2007) 1.32
Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J Immunol (2000) 1.26
Lipoxins: endogenous regulators of inflammation. Am J Physiol Renal Physiol (2004) 1.21
Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol (2004) 1.10
An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J Immunol (2002) 1.01
Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties. Bioorg Med Chem Lett (2008) 0.99
Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. J Med Chem (2004) 0.98
Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities. J Med Chem (2007) 0.94
Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell (2002) 19.15
A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem (2003) 15.88
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (2004) 13.04
Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature (2007) 6.53
Effect of iodine intake on thyroid diseases in China. N Engl J Med (2006) 5.46
Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med (2005) 5.00
TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science (2005) 4.86
Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem (2003) 4.58
Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol (2005) 4.30
Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A (2004) 4.28
Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med (2010) 4.23
Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature (2012) 4.04
Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem (2003) 3.80
Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs (2003) 3.70
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A (2010) 3.60
Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell (2012) 3.54
A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest (2005) 3.44
Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med (2008) 3.35
Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A (2005) 3.32
Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem (2007) 3.28
Multipotential differentiation of adipose tissue-derived stem cells. Keio J Med (2005) 3.28
Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature (2009) 3.27
A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell (2005) 3.22
Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol (2008) 3.15
Resolvins and protectins in inflammation resolution. Chem Rev (2011) 3.09
Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol (2006) 3.03
Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med (2002) 2.94
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol (2004) 2.86
Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol (2007) 2.83
Calorie restriction mimetics: an emerging research field. Aging Cell (2006) 2.82
The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev (2006) 2.80
Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 2.78
MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver Int (2012) 2.77
Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med (2002) 2.75
Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol (2006) 2.75
Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol (2008) 2.68
Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol (2007) 2.66
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr (2010) 2.64
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol (2009) 2.63
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood (2009) 2.61
Dietary deprivation extends lifespan in Caenorhabditis elegans. Aging Cell (2006) 2.54
B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci U S A (2013) 2.47
Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood (2012) 2.37
Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol (2006) 2.37
Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol (2006) 2.36
Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A (2004) 2.34
Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population. Nat Genet (2011) 2.32
Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol (2008) 2.32
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A (2006) 2.31
Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol (2003) 2.23
Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med (2008) 2.17
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol (2009) 2.11
Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol (2007) 2.11
Resolvins and protectins in the termination program of acute inflammation. Trends Immunol (2007) 2.06
Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A (2002) 2.01
Myogenic differentiation by human processed lipoaspirate cells. Plast Reconstr Surg (2002) 1.97
Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol (2013) 1.96
The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem (2005) 1.96
Novel proresolving aspirin-triggered DHA pathway. Chem Biol (2011) 1.93
Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest (2011) 1.92
Development of calorie restriction mimetics as a prolongevity strategy. Ann N Y Acad Sci (2004) 1.92
Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci U S A (2012) 1.91
Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol (2004) 1.91
Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med (2006) 1.90
Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res (2010) 1.89
MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J (2010) 1.87
Phosphoproteome analysis of isoflurane-protected heart mitochondria: phosphorylation of adenine nucleotide translocator-1 on Tyr194 regulates mitochondrial function. Cardiovasc Res (2008) 1.87
Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J (2012) 1.86
Epitaxial growth of single-domain graphene on hexagonal boron nitride. Nat Mater (2013) 1.84
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PLoS One (2010) 1.83
15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med (2009) 1.81